Meeting
2023 ASCO Annual Meeting
A comprehensive pan-cancer analysis of PD-L1 expression using clone E1L3N in Chinese patients with cancer.
Authors
Huangbin Lu
Department of Research and Development, Amoy Diagnostics Co., Ltd., Xiamen, China
Huangbin Lu , Zhan Huang , Huijuan Ge , Hongyu Wang , Li Ruan , Frank Zheng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other IO-Related Topics
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 2656)
DOI
10.1200/JCO.2023.41.16_suppl.2656
Abstract #
2656
Poster Bd #
498
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
The efficacy of immune checkpoint inhibitors in biliary tract cancer with KRAS mutation.
First Author: Sun Young Jeong
Poster
2022 ASCO Annual Meeting
Observer performance study to examine the feasibility of the AI-powered PD-L1 analyzer to assist pathologists’ assessment of PD-L1 expression using tumor proportion score in non–small cell lung cancer.
First Author: Seokhwi Kim
Poster
2021 ASCO Annual Meeting
Changes in PD-L1 tumor proportion score are associated with CD274 gene (encoding PD-L1) copy number variation in non-small cell lung cancer.
First Author: Stephanie Leigh Alden
Poster
2021 ASCO Annual Meeting
Clinical performance of artificial intelligence-powered annotation of tumor cell PD-L1 expression for treatment of immune-checkpoint inhibitor (ICI) in advanced non-small cell lung cancer (NSCLC).
First Author: Hyojin Kim